# Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

> **NCT02805660** · PHASE1,PHASE2 · TERMINATED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 83 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Mocetinostat - 50 mg
- **DRUG:** Mocetinostat - 70 mg
- **DRUG:** Mocetinostat - 90 mg
- **DRUG:** Mocetinostat - Recommended Phase 2 Dose (70 mg)
- **DRUG:** Durvalumab - 1500 mg

## Key facts

- **NCT ID:** NCT02805660
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-01
- **Primary completion:** 2019-12-14
- **Final completion:** 2019-12-20
- **Target enrollment:** 83 (ACTUAL)
- **Why stopped:** The study was discontinued early because the Sponsor de-prioritized development of mocetinostat. The decision to stop was not due to any patient safety issues.
- **Last updated:** 2021-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02805660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02805660, "Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02805660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*